INSIGHTS ON EMERGING CAR T THERAPIES

Scientists believe prostaglandin F2 receptor negative regulator (PTGFRN) is a possible target for chimeric antigen receptor (CAR) T-cell therapy in patients with glioblastoma (GBM). 

Researchers report the safety of a novel approach to insulate edited cells from chimeric antigen receptor (CAR) selection and attack.

Chimeric antigen receptor (CAR) T-cell treatments have suboptimal performance in the setting of chronic lymphocytic leukemia (CLL), but researchers have identified a potential pathway to increase...

In a multicenter retrospective study published in Blood Advances, authors from multiple institutions examined the impact of prior inotuzumab ozogamicin (InO) exposure on the outcomes of...

Researchers from University Hospital Ostrava and the Faculty of Medicine at the University of Ostrava, Czech Republic, conducted a comprehensive review on how intrinsic T cell characteristics...

Scientists are learning more about how T cell trogocytosis — the exchange of membrane-associated proteins between cells — is regulated, knowledge that could potentially unlock novel...